IBT is developing equine immunoglobulin therapeutic products (anti-GP F(ab')2) for filoviruses. This is a collaborative project between IBT, Auburn University, and Emergent Biosolutions (EBSI).
IBT and its collaborators have devised a novel immunization approach in horses to generate high titer plasma against Ebola, Sudan, and Marburg viruses. The hyperimmuneglobulin is de-speciated and used to treat infections. IBT’s equine immunoglobulin candidates have shown efficacy in vitro and in mouse models of filovirus infections.
The goal of IBT’s filovirus equine immunoglobulin therapeutic program is to develop an immunotherapy with primary indications for therapy and post-exposure prophylaxis of filovirus infections. The next step in our filovirus equine immunoglobulin program is to conduct further characterization and evaluation of the candidates, and then advance toward IND and clinical trials.